Medpace raises 2026 EPS guidance range

Medpace Holdings (MEDP) raised its 2026 diluted GAAP EPS guidance to $17.97-$18.32, exceeding the consensus of $17.59. The previous range was $17.25-$17.95. Full-year revenue outlook is $2.835B-$2.855B, with the midpoint below the consensus of $2.85B.

Original reporting
Published Oct 21, 2026, 10:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 10:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$MEDP
Bullish
high confidence
Mentioned
$MEDP
Relevance
7/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$MEDPBullishHigh
01

Why it matters

The upward EPS guidance could trigger a short‑cover rally and attract growth‑oriented investors.

02

Market read

Guidance raise is a primary catalyst for MEDP's stock, likely prompting price appreciation.

03

What to watch

Potential cost pressures or delayed trial timelines could offset earnings upside.

Relevance 7/10Novelty 8/10Timing: pre‑market today

Background

Medpace Holdings (NASDAQ:MEDP) is a contract research organization providing drug development services.

Company-level read

Ticker impact

$MEDPBullishHigh confidence
Context

Medpace raised its 2026 diluted GAAP EPS guidance to $17.97‑$18.32, above consensus.

Expected impact

upward pressure as the market prices in higher EPS expectations

Evidence & confidence

The EPS range now exceeds analyst consensus, indicating better profitability and likely prompting buying interest.

Market effects

May lift sentiment for the contract research organization sector.

Limited to U.S. biotech/health‑care investors.

Minimal global impact beyond sector peers.

Counterpoint

If revenue outlook remains below consensus, the EPS beat may not be sustainable.

Key entities

  • Medpace Holdings

    Contract research organization issuing the guidance.

Related articles

$MEDPMedAI 8/10

MEDP Q3 deep dive: bookings strength drives growth, margin expansion continues

MEDP reported Q3 revenue of $716M, beating estimates, with EPS of $4.84 and adjusted EBITDA of $172.1M. The company reconfirmed full-year revenue guidance of $2.85B and raised EPS guidance to $18.15. Growth was driven by strong bookings in oncology research and margin expansion from a favorable project mix. Management highlighted stable competition, low turnover, and sustained bookings momentum, but noted project cancellations as a watchpoint.

$MEDPMedAI 8/10

Medpace 3Q 2026: Revenue $716M, EPS $4.84— 10-Q Summary

Medpace Holdings reported Q3 2026 revenue of $716M, up 8.5% YoY, with net income rising 23.7% to $137.46M and EPS increasing 25.4% to $4.84. Growth was driven by Metabolic, Oncology, and CNS services. Nine-month revenue grew 16.9%, net awards reached $873.4M, and backlog increased 5.6% YoY to $3.17B. The company plans organic growth and selective acquisitions.

$MEDPHighAI 8/10

Medpace (MEDP) Q3 2026 Earnings Call Transcript

Medpace (MEDP) reported Q3 2026 revenue of $716M, up 8.5% YoY, with EBITDA of $172.1M (up 16%) and net income of $137.5M (up 23.7%). Guidance raised: revenue $2.835B-$2.855B (12-12.8% growth), EBITDA $638M-$652M (14.4-16.9% growth), EPS $17.97-$18.32. Board approved $1B share repurchase program. Net new business awards up 10.6% QoQ.

$MEDPMed

Medpace Q3 Earnings Call Highlights

Medpace reported a 10.6% year-over-year increase in net new business awards to $873.4 million in Q3, with a total 12-month backlog of $3.02 billion. Ending backlog was $3.2 billion, up 5.6% year-over-year. The company expects $1.99 billion of backlog to convert into revenue over the next year. Management noted shifts in therapeutic mix and strong pending opportunities. Medpace plans to provide 2027 guidance in February, with fourth-quarter awards and cancellations influencing the outlook.

$MEDPHighAI 8/10

Medpace Q3 2026 slides: record awards fuel profit beat, guidance raised

Medpace Holdings (NASDAQ:MEDP) reported Q3 2026 revenue of $716.0M, up 8.5% YoY, and adjusted earnings of $4.84 per share, exceeding estimates. Net income rose 23.7% to $137.5M, with EBITDA margin widening to 24.0%. The company raised its full-year guidance, citing record new business awards and strong profitability trends. Shares traded near $659.37, close to their 52-week high.